Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Acute myeloid leukemia (AML) is a blood and bone marrow cancer in which the bone marrow makes immature white blood cells called myeloblasts or "blasts." This kind of cancer is called "acute" rather than "chronic" because it tends to be a fast-growing
type of leukemia.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare subtype of AML. Learn more about our specialized BPDCN Center.
AML can be diagnosed at any age, but affects mostly older adults. The median age at diagnosis is 68 years.
Some patients with AML have no known risk factors for developing the disease. Recognized risk factors for AML include:
These symptoms can have many causes and may not be due to cancer. However, it is important that you discuss persistent symptoms with your primary care doctor.
AML is often a fast-growing disease, so timely and prompt diagnosis and initiation of treatment are important. Even though AML is usually a cancer of the blood and bone marrow, it can sometimes spread to other organs, such as the skin, brain, spinal cord,
As with any cancer, prognosis (chance of recovery) and long-term survival can vary greatly from patient to patient. The prognosis depends partly on:
New Patient Appointments